<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

Anne Staylor

Former Senior Editor, Medtech Insight. +25 years in various leadership roles in business intelligence, marketing, communications, product management, and consulting for medical device industry, hospitals, physician groups, insurers. Registered nurse and former Director of Marketing for a national ambulatory surgery company.

Recent Posts

3 min read

CSRS 2019: Highlights and Trends in Spine Research

By Anne Staylor on 11/27/19 1:26 PM

Julianne Burns, SmartTRAK's Senior Analyst, Spine, just returned from attending the 2019 Cervical Spine Research Society's (CSRS) 47th Annual Meeting in New York City.

Julianne discusses highlights from the meeting, including what’s on the horizon for the cervical spine market and the trend toward moving cervical spine procedures to an ASC setting in an interview with SmartTRAK Managing Editor Anne Staylor.

Click the video below to hear the interview, and scroll down to read the transcript.

Topics: Orthopedics
Continue Reading
13 min read

Rapid Medical: Innovative Strategies in Stroke Care

By Anne Staylor on 11/14/19 1:10 PM

Rapid Medical CEO Ronen Eckhouse discusses the Company’s latest innovations, the plan for bringing its novel neurovascular devices to market, and Rapid’s strategy for competing in the market for neurovascular devices in an interview with SmartTRAK

To listen to the interview, click on the following video. A transcript of the interview is also provided below, as is a link to download the transcript.

Continue Reading
3 min read

SNIS 2019: An Interview with Corindus Vascular Robotics

By Anne Staylor on 11/1/19 9:30 AM

Executives from Corindus Vascular Robotics discuss the Company’s plans and strategies for improving stroke care in an interview with SmartTRAK at SNIS 2019

Although Corindus Vascular Robotics is known more for playing in the cardiovascular space, the Company is now leveraging its expertise in vascular robotics to expand into neurovascular applications and telerobotics with the goal of improving access to comprehensive stroke care. The Company’s CorPath GRX System received FDA clearance for percutaneous coronary interventions in 2016 and for peripheral vascular interventions in 2018. Since then, the CorPath GRX has received ...

Continue Reading
2 min read

Insera Therapeutics: An Interview with the Founders

By Anne Staylor on 10/11/19 9:30 AM

Insera Therapeutics takes vacuum aspiration therapy to a new level with a disruptive digital design and cyclical aspiration for mechanical thrombectomy

Insera Therapeutics’ co-founders and brothers Vikram Janardhan and Vallabh Janardhan, MD saw an opportunity in the market for acute ischemic stroke and have developed a next generation, all digital vacuum aspiration system for mechanical thrombectomy designed to take suction aspiration to a new level. Unlike traditional analog electromechanical vacuum aspiration systems, which provide uniform, static aspiration, the Company’s CLEAR Aspiration System allows users to layer cyclical or pulsatile aspiration on top of uniform aspiration. By marrying a computer to a vacuum pump, Insera’s Clear Aspiration System can be finely controlled, and allows users to create their own cyclical wave patterns remotely using an iPad controller.

The Company recently received CE Mark for the Clear Aspiration System with a broad indication beyond stroke, and research to date suggests the technology provides better transmission suction to the tip, improves the first pass effect and decreases emboli in new territory.

To find out more about Insera Therapeutics, the technology and what’s next for the Company, SmartTRAK interviewed CEO Vikram Janardhan and Chief Medical Officer Vallabh Janardhan, MD, at the Society of Neurointerventional Surgery (SNIS) Annual Meeting in Miami Beach, FL held July 22-26, 2019.

Click on the following video to listen to SmartTRAK’s interview with Vikram and Vallabh Janardhan, MD, recorded live at SNIS 2019. To download a transcript of the interview, please click the button at the end of this post.

Continue Reading
5 min read

Q219 SCS Market Recap: Shares Shift Amid Ongoing Weakness

By Anne Staylor on 10/4/19 10:00 AM

Despite continued weakness and share shifts in Q219, the SCS market is poised to accelerate in H219 on new products/clinical data

In Q219, US and WW spinal cord stimulation (SCS) revenues were down for all the big players against tough YoY comps and ongoing weakness in the market as companies work through a gap in new product introductions, ongoing commercial execution issues and customer destocking. In the US, SCS revenues were down -6.3% vs Q218 according to the SmartTRAK Financial Dashboard. Although revenues were up sequentially per the usual seasonality in Q2, QoQ growth in Q219 was more anemic compared to the previous year. Between Q119-Q219, US SCS revenue was up just over ...

Among the many topics covered in the complete Q219 SCS Market Recap* are:

Continue Reading
29 min read

Intraoperative Neuromonitoring in SCS: An Interview with Steven Falowski, MD

By Anne Staylor on 5/22/19 9:30 AM

Intraoperative neuromonitoring could be a game changer in the field of SCS by elucidating the MOA for current and emerging SCS waveforms and stimulation patterns. But will it improve outcomes? To find out more, SmartTRAK interviewed Steven Falowski, MD at NANS 2019.

Steven Falowski, MD, Secretary of the Board for the North American Neuromodulation Society (NANS), discusses the latest research on the use of intraoperative neuromonitoring during spinal cord stimulation (SCS) in an interview with SmartTRAK at the NANS 22nd annual meeting held Jan. 17-20, 2019 in Las Vegas.

Historically, pain specialists have always placed spinal cord stimulators in awake patients for safety reasons and to confirm the therapy is adequately covering painful areas. However, Dr. Falowski says there’s been a paradigm shift where both pain physicians and surgeons alike are now using intraoperative neuromonitoring to place SCS systems for both percutaneous electrodes and paddle leads in asleep patients to more accurately localize the spinal cord midline and to improve intraoperative electrode placement and pain coverage... 

Continue Reading
32 min read

INS 2019 Preview: An Interview with INS President Robert Levy, MD

By Anne Staylor on 5/20/19 12:59 PM

In an interview with SmartTRAK, Robert Levy, MD, president of the International Neuromodulation Society (INS), provides a preview of the research, emerging technologies, and trends in neuromodulation that will be at the INS 2019 14th World Congress to be held May 23-30, 2019 in Sydney, Australia. 

The meeting will highlight several important topics, including the use of neurostimulation to reduce opioid use, closed-loop neurostimulation, and advances in non-invasive brain stimulation, including for the treatment of post-traumatic stress disorder, depression, and for enhancing memory and learning.

In terms of research, Dr. Levy said Sam Eldabe, MD of the United Kingdom will provide a critical evaluation of clinical trials in neuromodulation. Researchers will also present the latest insight into mechanism of action, new data on neurostimulation for cardiac ischemia, as well as research on use of deep brain stimulation (DBS) for obesity, eating disorders and addiction. Researchers will also present important pivotal trial results, including: the Evoke Study (Saluda Medical), evaluating closed-loop spinal cord stimulation (SCS); the SURF study (Stimwave Technologies), comparing different wireless SCS frequencies and waveforms; and the ReActiv8 trial (Mainstay Medical), evaluating the use of a restorative neurostimulation system for nocioceptive chronic low back pain. 

On the technology front, the INS’s Innovation Day will highlight disruptive innovations in neuromodulation, and will feature panel discussions and presentations by researchers and major shareholders from early stage start-ups, middle-stage start-ups and well-established companies.

To find out more about the INS World Congress, click on the following video to listen to SmartTRAK’s interview with Dr. Levy recorded via phone from his office in Florida. A transcript of the interview is also provided below.

Continue Reading
2 min read

NANS 2019: Highlights and Key Takeaways

By Anne Staylor on 5/7/19 7:30 AM

SmartTRAK highlights key takeaways from the recent North American Neuromodulation (NANS) 22nd annual meeting held in Las Vegas in January, including important company news, trials, technologies, and trends affecting the US market for spinal cord stimulation (SCS) and what's next in this market. This informative article also includes exclusive interviews with leading figures in Neuromodulation including Saluda Medical CEO John Parker, President Abbott Neuromodulation Keith Boetigger, Medtronic Senior VP and Pain Therapies President Marshall Stanton, and Medtronic Senior Global Product Manager for Pain Stimulation and Early Interventions Brian Ranck ...

Spotlight on Saluda Medical

In one of the most anticipated presentations at NANS 2019, Nagy Mekail, MD, PhD presented preliminary three-month results from Saluda Medical’s EVOKE US pivotal RCT (N=134), which is evaluating Saluda’s ECAP-controlled, closed-loop, Evoke SCS System. In the double-blinded study, the experimental arm (n=67) received closed-loop Evoke stimulation while the control arm (n=67) received fixed-output, open-loop Evoke SCS stimulation. At three months, the closed-loop group demonstrated superiority (Ps=0.005) having an 82.3% (51/62) success rate vs the open-loop group’s 60.3% (38/63) in 50% or greater reduction in overall Trunk and Limb VAS. The closed-loop group also met superiority (Ps=0.003) in terms of low back pain responders at three months with 80.6% demonstrating a 50% or greater reduction in back VAS versus 57.1% in the open-loop group. Of note, the closed loop Evoke group spent 91.1% of time (median % of stimuli) within the therapeutic window vs 59.5% of the time in the open-loop group.

In another presentation, Charles Brooker, MBChB presented updated results from the ongoing AVALON trial evaluating the safety and performance of 

Continue Reading
5 min read

Q418/FY18 Market Recap: SCS Market Slows

By Anne Staylor on 4/9/19 10:12 AM

The Spinal Cord Stimulation (SCS) market saw high-teens growth in FY18, but decelerated in Q418.

The US SCS Market saw another banner year in FY18, growing +17.4% YoY. Market growth was driven by new product launches, expanding indications and ongoing demand for non-narcotic alternatives that address chronic intractable pain and the opioid epidemic.

Continue Reading
4 min read

SmartTRAK attending International Stroke Conference 2019

By Anne Staylor on 1/23/19 10:24 AM

SmartTRAK is excited to be attending the AANS/CNS Joint Cerebrovascular Annual Meeting on Feb. 4-5, 2019 at the Sheraton Waikiki in Honolulu, Hawaii and the International Stroke Conference 2019, Feb 6-8, also in Honolulu.

Anne Staylor, Managing Editor, Business Intelligence and Senior Director, Advanced Technologies will be representing BioMedGPS SmartTRAK at both conferences. Please Contact Usif you would like a meeting!

Continue Reading

    Recent Articles